Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2011-01-11
2011-01-11
Chong, Kimberly (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S024310, C536S024100, C514S04400A
Reexamination Certificate
active
07868158
ABSTRACT:
The present invention relates to regulation of antigen presentation by cytokine signaling regulators in antigen presenting cells, such as dendritic cells. The invention provides methods of modulating antigen presentation through modulation of cytokine signaling regulators, such as SOCS (SOCS1-7, CIS), SHP (SHP-1 and SHP-2) or PIAS (PIAS1, PIAS3, PIASx and PIASy). The present invention provides vaccines and therapies in which antigen presentation is enhanced through modulation of cytokine signaling regulators. The present invention also provides a mechanism to break self tolerance in tumor vaccination methods that rely on presentation of self tumor antigens.
REFERENCES:
patent: 4082735 (1978-04-01), Jones et al.
patent: 4082736 (1978-04-01), Jones et al.
patent: 4101536 (1978-07-01), Yamamura et al.
patent: 4185089 (1980-01-01), Derrien et al.
patent: 4235771 (1980-11-01), Adam et al.
patent: 4406890 (1983-09-01), Tarcsay et al.
patent: 4606918 (1986-08-01), Allison et al.
patent: 4683202 (1987-07-01), Mullis et al.
patent: 4962091 (1990-10-01), Eppstein et al.
patent: 5023243 (1991-06-01), Tullis et al.
patent: 5168053 (1992-12-01), Altman et al.
patent: 5190931 (1993-03-01), Inouye
patent: 5199942 (1993-04-01), Gillis et al.
patent: 5350674 (1994-09-01), Boenisch et al.
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5585362 (1996-12-01), Wilson et al.
patent: 5710123 (1998-01-01), Heavner et al.
patent: 5710129 (1998-01-01), Lynch et al.
patent: 5928906 (1999-07-01), Koster et al.
patent: 6326193 (2001-12-01), Liu et al.
patent: 6716422 (2004-04-01), Gajewski et al.
patent: 2003/0138413 (2003-07-01), Vicari et al.
patent: 2003/0166140 (2003-09-01), Chen et al.
patent: 2003/0171253 (2003-09-01), Ma et al.
patent: 2003/0175971 (2003-09-01), Lindeman et al.
patent: 2004/0259247 (2004-12-01), Tuschl et al.
patent: 2005/0147608 (2005-07-01), Ryo et al.
patent: 2006/0239971 (2006-10-01), Mohapatra
patent: 2006/0292119 (2006-12-01), Chen et al.
patent: WO 92/07065 (1992-04-01), None
patent: WO 94/07529 (1994-04-01), None
patent: WO 01/29058 (2001-04-01), None
patent: WO 01/75164 (2001-10-01), None
patent: WO 01/96584 (2001-12-01), None
Akira et al. Toll-Like Receptor Signaling. Journal of Biological Chemistry 2003, vol. 278, No. 40: 38105-38108.
Brummelkamp et al. Stable Suprresion of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2002, pp. 243-247.
Matsuda et al. SOCS-1 can suppress CD3 and Syk-mediated NF-AT activation in a non-lymphoid cell line. FEBS Letters 2000, vol. 472: 235-240.
Rao et al. IL-12 Is an Effective Adjuvant to Recombinant Vaccinia Virus-Based Tumor Vaccines. Journal of Immunology 1996, vol. 156: 3357-3365.
Yamamoto et al. SOCS-3 inhibits IL-12 induced STAT4 activation by binding through tis SH2 domain to the STAT4 docking site in the IL-12 receptor B2 subunit. Bichem and Biophys Research Comm 2003, Vool. 310: 1188-1193.
Schnidt et al. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood 2003, vol. 102, No. 2: 571-576.
Song et al. Suppressor of Cytokine Signaling SOCS1 and SOCS3 but not SOCS2 proteines inhibit interferon-mediated antiviral and anti-proliferative activities. JBC, vol. 273, No. 52: pp. 35056-35062.
Akira et al., “Toll-like Receptor Signaling”, Nat. Rev. Immunol. 4:499-511 (2004).
Alexander et al., “SOCS1 Is a Critical Inhibitor of Interferon γ Signaling and Prevents the Potentially Fatal Neonatal Actions of the Cytokine”, Cell 98:597-608 (1999).
Alexander et al., “The Role of Suppressors of Cytokine Signaling (SOCS) Proteins in Regulation of the Immune Response”, Annu. Rev. Immunol. 22:503-29 (2004).
Baetz et al., “Suppressor of Cytokine Signaling (SOCS) Proteins Indirectly Regulate Toll-like Receptor Signaling in Innate Immune Cells”, J. Biol. Chem. 279:54708-54715 (2004).
Crespo et al., “Indirect induction of suppressor of cytokine signaling-1 in macrophages stimulated with bacterial lipopolysaccharide: partial role of autocrine/paracrine interferon-α/β”, Biochem. J. 349:99-104 (2000).
Curtisinger et al., “Signal 3 Determines Tolerance versus Full Activation of Naïve CD8 T Cells: Dissociating Proliferation and Development of Effector Function”, J. Exp. Med. 197:1141-1151 (2003).
Dalpke et al., “Suppressors of Cytokine Signaling (SOCS)-1 and SOCS-3 Are Induced by CpG-DNA and Modulate Cytokine Responses in APCs”, J. Immunol. 166:7082-7089 (2001).
Eyles et al., “Negative Regulation of Inerleukin-12 Signaling by Suppressor of Cytokine Signaling-1”, J. Biol. Chem. 277:43735-43740 (2002).
Hanada et al., “Suppressor of Cytokine Signaling-1 Is Essential for Suppressing Dendritic Cell Activation and Systemic Autoimmunity”, Immunity 19:437-450 (2003).
Kinjyo et al., “SOCS1/JAB Is a Negative Regulator of LPS-Induced Macrophage Activation”, Immunity 17:583-591 (2002).
Kubo et al., “Suppressors of cytokine signaling and immunity”, Nature Immunity 4:1169-1176 (2003).
Marine et al., “SOCS1 Deficiency Causes a Lymphocyte-Dependent Perinatal Lethality”, Cell 98:609-616 (1999).
Naka et al., “SOCS-1/SSSI-1-Deficient NKT Cells Participate in Severe Hepatitis through Dysregulated Cross-Talk Inhibition of IFN-γ and IL-4 Signaling In Vivo”, Immunity 14:535-545 (2001).
Nakagawa et al., “SOSC-1 Participates in Negative Regulation of LPS Responses”, Immunity 17:677-687 (2002).
Ryo et al., “Regulation of NF-κB Signaling by Pin 1-Dependent Prolyl Isomerization and Ubiquitin-Mediated Proteolysis of p65/ReIA”, Molecular Cell 12:1413-1426 (2003).
Valenzuela et al., “The Roles of IL-12 in Providing a Third Signal for Clonal Expansion of Naïve CD8 T Cells”, J. Immunol. 169:6842-6849 (2002).
Wormald et al., “Inhibitors of Cytokine Signal Transduction”, J. Biol. Chem. 279:821-824 (2004).
Heyninck, et al., “A20 Inhibits NF-κB Activation by Dual Ubiquitin-Editing Functions”,Trends Biochem Sci., Jan. 2005, vol. 1, pp. 1-4.
PCT International Search Report—(PCT/US2006/001751) Date of Mailing Aug. 14, 2008.
PCT International Search Report—(PCT/US2005/022396) Date of Mailing Jul. 15, 2008.
Agrwal et al., Oligodeoxynucleoside methylphosphonates: Synthesis and enzymic degradation,Tetrahedron Letters, 28:3539-3542, 1987.
Allen et al., Th1-Th2: reliable 392, 1997. paradigm or matrices dangerous dogma?,Immunol. Today, 18:387-392, 1997.
Altschul, Amino acid substitution matrices from an information theoretic perspective,J. Mol. Biol., 219:555-565, 1991.
Balazs et al., Blood dendritic cells interact with splenic marginal zone B Cells to initiate T-independent immune responses,Immunity, 17:341-352, 2002.
Banchereau et al., Autoimmunity through cytokine-induced dendritic cell activation,Immunity, 20:539-550, 2004.
Banchereau et al., Dendritic cells and the control of Immunity,Nature, 392:245-252, 1998.
Barron et al., Influence of plasma viremia on defects in number and immunophenotype of blood dendritic cel subsets in human immunodeficiency virus 1-infected individuals,J. Infect. Dir., 187:26-37, 2003.
Beutler et al., Innate immune sensing and its roots: the story of endotoxin,Nat. Rev. Immunol., 3:169-176, 2003.
Brummelkamp, et al., A system for stable expression of short interfering RNAs in mammalian cells,Science, 296:550-553, 2002.
Burton et al., HIV vaccine design and the neutralizing antibody problem,Nat. Immunol., 5:233-236, 2004.
Carbonneil et al., Defective dendritic cell function in HIV-infected patients receiving effective highly active antiretroviral therapy: neutralization of IL-10 production and depletion of CD4+CD25+cells restore high levels of HIV-specific CD4+T cell responses induced by dendritic cells generated in the presence of IFN-α1,J. Immunol., 172:7832-7840, 2004.
Cech et al., RNA catalysis by a group 1 ribozyme,J. Biol. Chem., 267:17479-17482, 1992.
Chen Si-Yi
Evel-Kabler Kevin C.
Huang Xue F.
Shen Lei
Baylor College of Medicine
Chong Kimberly
Ewing James F.
Foley & Lardner LLP
LandOfFree
Modulation of cytokine signaling regulators and applications... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulation of cytokine signaling regulators and applications..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulation of cytokine signaling regulators and applications... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2688654